Dong-A ST announced on the 20th that it announced the results of a preclinical study of the immuno-cancer drug candidate "DA-4505" at the American Association for Cancer Research, AACR) 2023 held in Orlando, Florida from the 14th to the 19th. The American Cancer Research Association is called the world's top three cancer societies, and is an annual academic conference where pharmaceutical bio companies from 120 countries participate to share cancer-related knowledge and research results. At the conference, Dong-A ST announced the "anti-tumor effect of DA-4505, a new aryl hydrocarbon receptor antagonist as an immune treatment in a tumor microenvironment," and "improving the efficacy of anticancer surgery and chemother